We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
This is the second patent issued in the antibody portfolio created through MabVax's unique discovery platform, which uses blood samples from patients vaccinated with selected tumor associated carbohydrate antigens.